Literature DB >> 17227983

The role of litigation in defining drug risks.

Aaron S Kesselheim1, Jerry Avorn.   

Abstract

Mesh:

Year:  2007        PMID: 17227983     DOI: 10.1001/jama.297.3.308

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  14 in total

1.  Medical reversal: why we must raise the bar before adopting new technologies.

Authors:  Vinay Prasad; Adam Cifu
Journal:  Yale J Biol Med       Date:  2011-12

2.  A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Authors:  Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

3.  Hidden in plain sight marketing prescription drugs to consumers in the twentieth century.

Authors:  Jeremy A Greene; David Herzberg
Journal:  Am J Public Health       Date:  2010-03-18       Impact factor: 9.308

4.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

Review 5.  Approval of high-risk medical devices in the US: implications for clinical cardiology.

Authors:  Benjamin N Rome; Daniel B Kramer; Aaron S Kesselheim
Journal:  Curr Cardiol Rep       Date:  2014       Impact factor: 2.931

Review 6.  The determination and interpretation of the therapeutic index in drug development.

Authors:  Patrick Y Muller; Mark N Milton
Journal:  Nat Rev Drug Discov       Date:  2012-08-31       Impact factor: 84.694

7.  Sorrell v. IMS Health: issues and opportunities for informaticians.

Authors:  Carolyn Petersen; Paul Demuro; Kenneth W Goodman; Bonnie Kaplan
Journal:  J Am Med Inform Assoc       Date:  2012-10-27       Impact factor: 4.497

8.  Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial.

Authors:  Samuel D Krumholz; David S Egilman; Joseph S Ross
Journal:  Arch Intern Med       Date:  2011-06-27

Review 9.  Comparative epidemiology of hospital-acquired adverse drug reactions in adults and children and their impact on cost and hospital stay--a systematic review.

Authors:  Lateef Mohiuddin Khan
Journal:  Eur J Clin Pharmacol       Date:  2013-08-17       Impact factor: 2.953

10.  Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.

Authors:  Domenico Motola; Antonio Vargiu; Roberto Leone; Anita Conforti; Ugo Moretti; Alberto Vaccheri; Giampaolo Velo; Nicola Montanaro
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.